Takeda Pharmaceutical (TAK) reported fiscal Q3 core earnings Thursday of 132 Japanese yen ($0.84) per basic share, down from 150 yen a year earlier.
Four analysts polled by FactSet expected 124 yen.
Revenue for the quarter ended Dec. 31 was 1.144 trillion yen, up from 1.111 trillion yen a year earlier.
Analysts surveyed by FactSet expected 1.138 trillion yen.
The company now expects core earnings guidance for the fiscal year ended March 31 to be 507 yen per share, compared with its prior guidance of 456 yen set on Oct. 31, 2024.
Analysts surveyed by FactSet expect 480 yen.
The company now expects revenue for the fiscal year of 4.59 trillion yen, compared with its prior guidance of 4.48 trillion yen. A single analyst polled by FactSet expects 4.562 trillion yen.
Shares of the company rose 3.5% in premarket activity Thursday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。